Literature DB >> 7099766

Intestinal bile acid malabsorption in cystic fibrosis: a primary mucosal cell defect.

J D Fondacaro, J E Heubi, F W Kellogg.   

Abstract

Bile acid malabsorption in cystic fibrosis reduces intraluminal bile acid concentration and may impair fat absorption. The cause of this malabsorption is unknown but it is believed due to intraluminal inhibition of uptake by undigested dietary nutrients. The purpose of this study was to determine the bile acid absorptive capability of cystic fibrosis intestine in a physiologic environment. Direct ileal mucosal taurocholic acid uptake was examined in vitro in seven patients with cystic fibrosis, and seven children and adolescents with ileostomies as controls. Jejunal uptake was studied in five normal individuals. A Crosby-Kugler biopsy capsule was used to obtain all tissues. Tissue was incubated in Krebs buffer, 10 mM glucose, and taurocholic acid at 0.1, 1.0 and 10.0 mM with shaking at 37 degrees C. Significant reduction of taurocholic acid uptake was present in every cystic fibrosis patient with mean uptake rates being 24%, 38%, and 29% of control ileum, respectively, at the three concentrations. Values paralleled those for passive jejunal taurocholic acid uptake in controls. These data illustrate a marked reduction in taurocholic acid uptake capability of cystic fibrosis ileal mucosa and may indicate a cellular defect suggestive of a primary lesion in this disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7099766     DOI: 10.1203/00006450-198206000-00019

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  23 in total

Review 1.  Cystic fibrosis, pathophysiological and clinical aspects.

Authors:  H J Neijens; M Sinaasappel; R de Groot; J C de Jongste; S E Overbeek
Journal:  Eur J Pediatr       Date:  1990-08       Impact factor: 3.183

2.  Liver and biliary problems in cystic fibrosis.

Authors:  M S Tanner
Journal:  J R Soc Med       Date:  1992       Impact factor: 5.344

Review 3.  Drug disposition in cystic fibrosis.

Authors:  E Rey; J M Tréluyer; G Pons
Journal:  Clin Pharmacokinet       Date:  1998-10       Impact factor: 6.447

4.  Defects in gallbladder emptying and bile Acid homeostasis in mice with cystic fibrosis transmembrane conductance regulator deficiencies.

Authors:  Dominique Debray; Dominique Rainteau; Véronique Barbu; Myriam Rouahi; Haquima El Mourabit; Stéphanie Lerondel; Colette Rey; Lydie Humbert; Dominique Wendum; Charles-Henry Cottart; Paul Dawson; Nicolas Chignard; Chantal Housset
Journal:  Gastroenterology       Date:  2012-02-24       Impact factor: 22.682

5.  Diuretic effect and disposition of furosemide in cystic fibrosis.

Authors:  J Prandota; I J Smith; B C Hilman; J T Wilson
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

6.  Effect of dietary fat and residues on fecal loss of sterols and on their microbial degradation in cystic fibrosis.

Authors:  C Leroy; G Lepage; C L Morin; J M Bertrand; O Dufour-Larue; C C Roy
Journal:  Dig Dis Sci       Date:  1986-09       Impact factor: 3.199

Review 7.  Clinical pharmacology of antibiotics and other drugs in cystic fibrosis.

Authors:  J Prandota
Journal:  Drugs       Date:  1988-05       Impact factor: 9.546

8.  Conjugated bile acids in serum and secretions in response to cholecystokinin/secretin stimulation in children with cystic fibrosis.

Authors:  T A Robb; G P Davidson; C Kirubakaran
Journal:  Gut       Date:  1985-11       Impact factor: 23.059

9.  Bile acid sequestration by the solid phase of stools in cystic fibrosis patients. Role of pancreatic enzymes.

Authors:  A Jonas; A Diver-Haber
Journal:  Dig Dis Sci       Date:  1988-06       Impact factor: 3.199

10.  Intestinal bile acid malabsorption in cystic fibrosis.

Authors:  S O'Brien; H Mulcahy; H Fenlon; A O'Broin; M Casey; A Burke; M X FitzGerald; J E Hegarty
Journal:  Gut       Date:  1993-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.